Nature GeneticsGenetic & Genomic MedicinePeer-reviewed journal article
Genetics of Myocardial Interstitial Fibrosis in the Human Heart and Association with Disease
Victor D. NauffaliD, Paolo Di AchilleiD, Marcus D. R. KlarqvistiD, Jonathan W. CunninghamiD, Matthew C. HilliD, James P. PirruccelloiD, Lu-Chen C WengiD, Valerie N. MorrilliD, Seung Hoan ChoiiD, Shaan S. KhurshidiD, Sam Freesun FriedmaniD, Mahan NekouiiD, Carolina RoselliiD, Kenney NgiD, Anthony PhilippakisiD, Puneet BatraiD, Patrick T. EllinoriD, Steven A. LubitziD
Abstract
Myocardial interstitial fibrosis is a common thread in multiple cardiovascular diseases including heart failure, atrial fibrillation, conduction disease and sudden cardiac death. To investigate the biologic pathways that underlie interstitial fibrosis in the human heart, we developed a machine learning model to measure myocardial T1 time, a marker of myocardial interstitial fibrosis, in 42,654 UK Biobank participants. Greater T1 time was associated with impaired glucose metabolism, systemic inflammation, renal disease, aortic stenosis, cardiomyopathy, heart failure, atrial fibrillation and conduction disease. In genome-wide association analysis, we identified 12 independent loci associated with native myocardial T1 time with evidence of high genetic correlation between the interventricular septum and left ventricle free wall (r2g = 0.82). The identified loci implicated genes involved in glucose homeostasis (SLC2A12), iron homeostasis (HFE, TMPRSS6), tissue repair (ADAMTSL1, VEGFC), oxidative stress (SOD2), cardiac hypertrophy (MYH7B) and calcium signaling (CAMK2D). Transcriptome-wide association studies highlighted the role of expression of ADAMTSL1 and SLC2A12 in human cardiac tissue in modulating myocardial tissue characteristics and interstitial fibrosis. Harnessing machine learning to perform large-scale phenotyping of interstitial fibrosis in the human heart, our results yield novel insights into biologically relevant pathways for myocardial fibrosis and prioritize investigation of pathways for the development of anti-fibrotic therapies.
- organism: human
- assay: GWAS summary statistics
- research focus: GWAS / association mapping
- approach: statistical model
- Citations
- 94
- FWCI
- 18.08
- Field percentile
- top 1%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Targeting the Immune-Fibrosis Axis in Myocardial Infarction and Heart Failure
J. M. Amrute, X. Luo, … K. Lavine·bioRxiv·Oct 17, 2022
- Interleukin 11-induced microRNAs as functional mediators and circulating biomarkers of cardiac fibrosis
Roman Tikhomirov, Veronika Boichenko, … Julia Gorelik·Circulation ResearchPeer-reviewed·Mar 17, 2026
- FAM114A1 Influences Cardiac Fibrosis by Regulating Angiotensin II Signaling in Cardiac Fibroblasts
K. C. V. Subbaiah, J. Wu, … P. Yao·bioRxiv·Feb 20, 2021
- Cardiomyocyte-restricted expression of IL11 causes cardiac fibrosis, inflammation, and dysfunction.
Mark D. Sweeney, Katie O’Fee, … Stuart A. Cook·International Journal of Molecular SciencesPeer-reviewed·Aug 20, 2023
- Interleukin-1β Drives Disease Progression in Arrhythmogenic Cardiomyopathy
Vinay R. Penna, Junedh Amrute, … Stephen P. Chelko·JACC Basic to Translational SciencePeer-reviewed·May 5, 2026
- Dysferlin is a novel regulator of COMP-positive matrifibrocytes in heart failure
Ievgeniia Kocherova, Muriel Giger, … Gabriela Kania·bioRxiv·Aug 21, 2026